阿托伐他汀对HepG2细胞中脂代谢相关基因表达的影响

doi:10.13481/j.1671-587x.20190115

摘要/Abstract

摘要： 目的：探讨阿托伐他汀对HepG₂细胞中载脂蛋白A1（apoA1）天然反义转录（apoA1-NAT）的作用及对脂代谢相关基因表达的影响。方法：采用不同浓度阿托伐他汀（0、1、10和100 nmol·L^-1）干预HepG₂细胞，0 nmol·L^-1阿托伐他汀组为对照组，在不同时间点（6、12、24和48h）提取各组HepG₂细胞总RNA，采用Real-time PCR法检测HepG₂细胞中apoA1-NAT和脂代谢相关基因mRNA表达水平。结果：1和10 nmol·L^-1阿托伐他汀组HepG₂细胞形态正常。与6 h时比较，12、24和48h时10 nmol·L^-1阿托伐他汀组HepG₂细胞中apoA1-NAT表达水平明显降低（P<0.01），且呈明显的时间依赖性。在相同条件下，48h时HepG₂细胞中apoA1 mRNA表达水平较6h时明显升高（P<0.01）。与对照组比较，100 nmol·L^-1阿托代他汀组HepG₂细胞中低密度脂蛋白受体（LDLR）、10 nmol·L^-1阿托代他汀组HepG₂细胞中清道夫受体B1（SRB1）及1和10 nmol·L^-1阿托伐他汀组HepG₂细胞中ATP结合盒式转运体A1（ABCA1）表达水平均有不同程度升高（P<0.01）。结论：阿托伐他汀通过抑制HepG₂细胞中apoA1-NAT表达，促进脂代谢相关基因表达，进而促进胆固醇逆转运过程。

关键词: 阿托伐他汀, 载脂蛋白A1, 载脂蛋白A1天然反义转录, 脂代谢, HepG₂细胞

Abstract: Objective: To explore the effects of atorvastatin on the natural antisense transcription of apolipoprotein A1 (apoA1-NAT) in the HepG₂ cells and its influence in the expressions of lipid metabolism related genes.Methods: The HepG₂ cells were intervened with different concentrations(0,1,10 and 100 nmol·L^-1) of atorvastatin, and the 0 nmol·L^-1 atorvastatin group was used as control group.The total RNA of HepG₂ cells in various groups were extracted at different time points(6,12,24, and 48 h). The mRNA expression levels of lipid metabolism-related genes and apoA1-NAT expression levels were detected by Real-Time PCR method.Results: The morphology of HepG₂ cells in 1 and 10 nmol·L^-1 atorvastain groups was normal.Compared with 6 h, the expression levels of apoA1-NAT in the HepG₂ cells in 10 nmol·L^-1 atorvastatin group at 12, 24 and 48 h were significantly decreased (P<0.01) in a time-dependent manner. Under the same condition, the expression level of apoA1 mRNA in the HepG₂ cells at 48 h was increased significantly compared with 6 h (P<0.01).Compared with control group, the expression levels of low density lipoprotein receptor(LDLR) in the HepG₂ cells in 100 nmol·L^-1 atorvastatin group,scavenger receptor-class B type 1 (SRB1) in 10 nmol·L^-1 atorvastatin group and ATP binding cassette transporter A1(ABCA1) in 1 and 10 nmol·L^-1 atorvastatin groups were increased(P<0.01) in different degrees.Conclusion: Atorvastatin can promote the expressions of lipid metabolism-related genes by inhibiting the expression of apoA1-NAT, and promote the process of reverse cholesterol transport.

Key words: atorvastatin, apolipoprotein A1, natural antisense transcription of apolipoprotein A1, lipid metabolism, HepG₂ cells

中图分类号:

R543.5

王艳丽, 黄鸣宇, 张鹏. 阿托伐他汀对HepG₂细胞中脂代谢相关基因表达的影响[J]. 吉林大学学报(医学版), 2019, 45(01): 77-82.

WANG Yanli, HUANG Mingyu, ZHANG Peng. Effects of atorvastatin on expression of lipid metabolism-related genes in HepG₂ cells[J]. Journal of Jilin University(Medicine Edition), 2019, 45(01): 77-82.

参考文献

[1] KAPURIA D,TAKYAR V K,ETZION O, et al. Association of hepatic steatosis with subclinical atherosclerosis:systematic review and Meta-analysis[J]. Hepatol Commun, 2018,2(8):873-883.
[2] GAO S,ZHAO D,WANG M, et al. Association between circulating oxidized LDL and atherosclerotic cardiovascular disease:A Meta-analysis of observational studies[J]. Can J Cardiol, 2017,33(12):1624-1632.
[3] FADAEI R,POUSTCHI H,MESHKANI R, et al. Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis[J]. Sci Rep, 2018,8(1):11691.
[4] KYPREOS K E,GKIZAS S,RALLIDIS L S, et al. HDL particle functionality as a primary pharmacological target for HDL-based therapies[J]. Biochem Pharmacol, 2013,85(11):1575-1578.
[5] MORA S,GLYNN R J,RIDKER P M. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy[J]. Circulation, 2013,128(11):1189-1197.
[6] WANGY,NⅡMIM,NISHIJIMAK, et al.Human Apolipoprotein A-Ⅱ protects against diet-Induced atherosclerosis in transgenic rabbits[J]. Arterioscler Thromb Vasc Biol, 2013,33(2):224-231.
[7] ROSENSON R S,BREWER HB,DAVIDSON W S, et al. Cholesterol efflux and atheroprotection:advancing the concept of reverse cholesterol transport[J]. Circulation, 2012, 125(15):1905-1919.
[8] COOKE A L,MORRIS J,MELCHIOR J T, et al. A thumbwheel mechanism for APOA1 activation of LCAT activity in HDL[J]. J Lipid Res, 2018,59(7):1244-1255.
[9] UCHIDA S,DIMMELER S. Long noncoding RNAs in cardiovascular diseases[J]. Circ Res,2015,116(4):737-750.
[10] HALLEY P,KADAKKUZHA B M,FAGHIHI M A, et al. Regulation of the apolipoprotein gene cluster by a long noncoding RNA[J]. Cell Rep, 2014, 6(1):222-230.
[11] COVEY S D,KRIEGER M,WANG W,et al. Scavenger receptor class B type Ⅰ-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells[J]. Arterioscler Thromb Vasc Biol, 2003, 23(9):1589-1594.
[12] RUBIN E M,KRAUSS R M,SPANGLER E A, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI[J]. Nature, 1991, 353(6341):265-267.
[13] ZHANG Y,ZANOTTI I,REILLY M P, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo[J]. Circulation, 2003,108(6):661-663.
[14] DUVERGER N,KRUTH H,EMMANUEL F, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits[J]. Circulation, 1996, 94(4):713-717.
[15] IKENAGA M,HIGAKI Y,SAKU K, et al. High-density lipoprotein mimetics:a therapeutic tool for atherosclerotic diseases[J]. J Atheroscler Thromb, 2016, 23(4):385-394.
[16] FAGHIHI M A,WAHLESTEDT C. Regulatory roles of natural antisense transcripts[J]. Nat Rev Mol Cell Biol, 2009, 10(9):637-643.
[17] WAHLESTEDT C. Natural antisense and noncoding RNA transcripts as potential drug targets[J].Drug Discov Today, 2006, 11(11/12):503-508.
[18] LEHNER B,WILLIAMS G,CAMPBELL R D, et al. Antisense transcripts in the human genome[J]. Trends Genet, 2002, 18(2):63-65.
[19] 张鹏, 王艳丽, 郭世文,等. 家兔胆固醇酯转移蛋白基因克隆及其真核表达载体的构建[J]. 吉林大学学报:医学版,2013,39(4):837-840.
[20] SHRESTHA S,WU B J,GUINEY L, et al. Cholesteryl ester transfer protein and its inhibitors[J]. J Lipid Res,2018,59(5):772-783.

阿托伐他汀对HepG₂细胞中脂代谢相关基因表达的影响

Effects of atorvastatin on expression of lipid metabolism-related genes in HepG₂ cells

RichHTML

PDF (PC)

赞

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	苗向霞, 郭蕊, 张璎, 卫银银, 罗正奇, 闵亚丽, 刘凯歌. 白藜芦醇对肝癌HepG₂细胞中脂肪合成的抑制作用及其机制[J]. 吉林大学学报(医学版), 2019, 45(01): 69-72.
[2]	苏寒, 张美家, 王怀杰, 李娜, 霍连广, 李桂芝, 戴功, 高志芹, 杨晓云, 曲梅花. Exendin-4对胰岛素抵抗人肝癌HepG₂细胞脂代谢相关因子基因表达的影响[J]. 吉林大学学报(医学版), 2018, 44(01): 36-40.
[3]	赵燕颖, 王秀岩, 秦国涛, 孙远杰, 刘志忠, 李然伟. 血管内皮生长因子165b对人肝癌HepG₂细胞生物学特性的影响[J]. 吉林大学学报(医学版), 2018, 44(01): 101-105.
[4]	包书茵, 韩淑英, 王胡格吉乐图, 包文山, 奥·乌力吉. 沙蓬粗寡糖对糖尿病GK大鼠一般表征和糖脂代谢的改善作用[J]. 吉林大学学报(医学版), 2016, 42(06): 1059-1065.
[5]	杜彪, 谢星星, 张杰, 范小冬, 叶云. 瑞舒伐他汀治疗中国原发性高胆固醇血症患者疗效与安全性的系统评价[J]. 吉林大学学报(医学版), 2016, 42(05): 968-974.
[6]	张宁, 王颖娴, 胡健, 郑婕, 王晓琴. 血清CA199、C3、C4及脂类代谢水平在胰腺癌临床诊断中的应用[J]. 吉林大学学报(医学版), 2016, 42(02): 295-300.
[7]	周明, 王雪雯, 杨莉, 宋海林, 段晶晶. As₂O₃联合γ分泌酶抑制剂对HepG₂细胞凋亡的诱导作用及其机制[J]. 吉林大学学报(医学版), 2015, 41(03): 470-475.
[8]	. 阿托伐他汀对同型半胱氨酸作用下人脐静脉内皮细胞Bcl-2启动子区甲基化水平的影响及其抗动脉粥样硬化机制[J]. 吉林大学学报(医学版), 2014, 40(05): 1002-1006.
[9]	石博，黄可欣，叶保国，张艳，黄可敬. 阿托伐他汀预处理对大鼠心肌缺血再灌注后不同时间点心肌组织中HIF-α和VEGF表达的影响[J]. 吉林大学学报(医学版), 2013, 39(6): 1159-1163.
[10]	黄可欣, 石博, 叶保国, 宋雪松 . 阿托伐他汀对心肌缺血再灌注损伤大鼠心肌酶和心肌细胞凋亡的影响及其心肌保护作用机制[J]. 吉林大学学报(医学版), 2013, 39(5): 923-927.
[11]	刘松岩,张晓君,才华,杨丽亚,丁晓娜,常颖. 不同剂量阿托伐他汀对国人颈动脉粥样硬化影响的Meta分析[J]. 吉林大学学报(医学版), 2013, 39(2): 313-317.
[12]	张敏\|宁亚媛\|张晶\|陈丽娟. ActRⅡA介导阿托伐他汀对动脉粥样硬化的治疗作用[J]. J4, 2012, 38(1): 54-57.
[13]	林述凯, 石秋艳, 王淑歌, 田广平, 张国志. 阿托伐他汀对实验性自身免疫性脑脊髓炎大鼠脊髓内NF-κB表达的影响[J]. J4, 2011, 37(4): 607-611.
[14]	郑雁, 孟霖, 董均树, 吴金义. 卡维地洛对老年舒张性心力衰竭患者心功能及糖、脂代谢的影响[J]. J4, 2009, 35(6): 1111-1114.
[15]	刘冷，徐华丽，于晓风，曲绍春，梁启明，睢大员. 苦碟子口服液对实验性高脂蛋白血症大鼠的保护作用[J]. J4, 2008, 34(5): 794-798.